|
|
Statistics
Categories: 160
Subcategories: 0
Total Posts/Links: 3622
Pending: 1
Today: 0
|
|
|
| ID: | 112 | | Title: | A late phase ii study of s-1 for metastatic pancreatic cancer - http://www.springerlink.com/content/h47552033603213l/ | | Description: | Abstract This study evaluated the antitumor effect and safety of S-1, an oral fluoropyrimidine derivative, in patients with metastatic
pancreatic cancer. Chemo-naive patients with pancreatic adenocarcinoma, and measurable metastatic lesions were enrolled. S-1
was administered orally twice daily after meals at a dose of 80, 100, or 120 mg/day for body surface areas (BSAs) of less
than 1.25 m2, between 1.25 m2 and less than 1.5, or 1.5 m2 or greater, respectively, for 28 consecutive days, followed by a 14-day rest. Fifteen (37.5%) of 40 patients responded to
treatment, including 1 complete response and 14 partial responses. The median time to progression and the overall survival
time were 3.7 months (95% confidence interval, 2.2–5.6 months) and 9.2 months (95% confidence interval, 7.5–10.8 months),
respectively. The major adverse events were anorexia, fatigue, hemoglobin reduction, nausea and pigmentation change, although
most were tolerable and reversible. Although disseminated intravascular coagulation occurred in two patients, the condition
resolved with anticoagulant therapy. S-1 is an effective and well-tolerated drug. The effectiveness of this drug should be
confirmed in a phase III study.
Content TypeJournal Article
JournalCancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) | | Category: | Anorexia Nervosa | | Link Owner: | | | Date Added: | May 23, 2007 12:53:32 PM | | Number Hits: | 0 | | |
|
